keyword
MENU ▼
Read by QxMD icon Read
search

CT-P13

keyword
https://www.readbyqxmd.com/read/28417494/editorial-ct-p13-a-biosimilar-of-anti-tumour-necrosis-factor-alpha-agent-infliximab-in-inflammatory-bowel-diseases-authors-reply
#1
EDITORIAL
Y Komaki, A Yamada, F Komaki, D Micic, A Ido, A Sakuraba
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28417492/editorial-ct-p13-a-biosimilar-of-anti-tumour-necrosis-factor-alpha-agent-infliximab-in-inflammatory-bowel-diseases
#2
EDITORIAL
R Felwick, J R F Cummings
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28293938/effectiveness-and-safety-of-infliximab-biosimilar-ct-p13-in-treating-ulcerative-colitis-a-real-life-experience-in-ibd-primary-centers
#3
Antonio Tursi, Leonardo Allegretta, Stefania Chiri, Nicola Della Valle, Walter Elisei, Giacomo Forti, Roberto Lorenzetti, Giammarco Mocci, Antonio Penna, Giuseppe Pranzo, Cristina Ricciardelli, Marcello Picchio
BACKGROUND: To assess the efficacy and safety of biosimilar infliximab (IFX) IFX CT-P13 in inducing and maintain remission in Ulcerative Colitis (UC) outpatients in Italian primary gastroenterology centers. METHODS: Patients were prospectively assessed at entry, after 8, 12, 24, 36, and therefore 52 weeks. Clinical activity was scored according to the Mayo score. The primary endpoint was reaching of clinical remission (Mayo score ≤2). Several secondary endpoints were clinical response to treatment, reaching of mucosal healing (MH), safety of the drug...
March 14, 2017: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/28281165/effectiveness-and-safety-of-ct-p13-biosimilar-infliximab-in-patients-with-inflammatory-bowel-disease-in-real-life-at-6%C3%A2-months
#4
F Argüelles-Arias, M F Guerra Veloz, R Perea Amarillo, A Vilches-Arenas, L Castro Laria, B Maldonado Pérez, D Chaaro, A Benítez Roldán, V Merino, G Ramírez, A Caunedo Álvarez, M Romero Gómez
BACKGROUND: CT-P13 is a biosimilar of Remicade(®), an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. AIMS: To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice. METHODS: This is a prospective observational study in patients with moderate to severe Crohn's disease or ulcerative colitis treated with CT-P13...
May 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28239873/systematic-review-with-meta-analysis-the-efficacy-and-safety-of-ct-p13-a-biosimilar-of-anti-tumour-necrosis-factor-%C3%AE-agent-infliximab-in-inflammatory-bowel-diseases
#5
REVIEW
Y Komaki, A Yamada, F Komaki, D Micic, A Ido, A Sakuraba
BACKGROUND: Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become clinically available for the treatment of inflammatory bowel diseases (IBD). AIM: We performed a systematic review and meta-analysis to evaluate the efficacy and safety of biosimilars of anti-TNF-α agents in patients with IBD. METHODS: Electronic databases were searched. The outcomes were the pooled rates of clinical response or remission, sustained clinical response or remission, and adverse events in patients with IBD induced with or switched to biosimilars of anti-TNF-α agents...
February 26, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28176515/biosimilars-in-inflammatory-bowel-disease
#6
Carla J Gargallo, Alberto Lué, Fernando Gomollón
The introduction of biologic therapies has revolutionized the treatment of inflammatory bowel disease (IBD) and has significantly improved the disease course and outcomes for many patients. Biologics are the main drivers of cost in many IBD units and biosimilars, although are not better than originators, are usually cheaper and thus can increase the availability of this type of therapy. Biosimilar are highly similar to innovator but, due to the complex structures of innovators and the variability inherent in the manufacturing process, they are no identical...
June 2017: Minerva Medica
https://www.readbyqxmd.com/read/28175254/p661-comparable-clinical-efficacy-safety-and-immunogenicity-of-infliximab-biosimilar-ct-p13-after-transition-from-reference-infliximab-remicade%C3%A2-in-children-with-established-inflammatory-bowel-disease-a-multi-centre-prospective-observational-study
#7
M Sladek, A Vultaggio, S Ghione, F Nencini, A Matucci, S Pratesi, F Zanieri, P M Maggi, M Paci, K Ponanta-Gawron, K Kulig, A Wasilewska, P Lionetti
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175221/p665-unchanged-infliximab-serum-concentrations-after-switching-from-the-reference-infliximab-to-the-biosimilar-ct-p13-in-patients-with-quiescent-crohn-s-disease-a-prospective-study
#8
A Strik, W van de Vrie, Y van Megen, J Bloemsaat-Minekus, T Rispens, G D'Haens
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175213/p679-infliximab-biosimilar-ct-p13-in-inflammatory-bowel-disease-patients-that-require-intensification-treatment
#9
M Gompertz, I Alfaro, E Ricart, A Lόpez, J Panés, M Gallego, R Barastegui, A Giner, A Vara, M Masamunt, I Ordás
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175208/p633-antibodies-to-infliximab-in-patients-treated-with-either-the-reference-biologic-or-the-biosimilar-ct-p13-show-identical-reactivity-towards-biosimilars-ct-p13-and-sb2-in-inflammatory-bowel-disease
#10
G Fiorino, M B Ruiz-Agüello, A Maguregui, D Nagore, S Radice, D Gilardi, C Correale, M Allocca, F Furfaro, M Alfieri, A Martínez, S Danese
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175199/p675-infliximab-biosimilar-ct-p13-therapy-is-effective-in-maintaining-clinical-remission-in-crohn-s-disease-and-ulcerative-colitis-54-week-data
#11
T Molnár, K Farkas, M Rutka, T Ferenci, F Nagy, A Bálint, R Bor, A Milassin, A Fábián, Z Végh, Z Kürti, P L Lakatos, Z Szepes
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175187/p586-a-novel-approach-to-the-implementation-of-biosimilar-infliximab-ct-p13-for-the-treatment-of-ibd-utilising-therapeutic-drug-monitoring-the-edinburgh-experience
#12
N Plevris, A Deekae, G R Jones, T A Manship, C L Noble, J Satsangi, A G Shand, I D Arnott, C W Lees
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175166/p605-rapid-detection-of-anti-infliximab-antibodies-in-inflammatory-bowel-disease-patients-treated-with-the-reference-biologic-or-the-biosimilar-ct-p13-performance-comparison-with-elisa
#13
G Fiorino, A Ametzazurra, D Nagore, A M Hernández, N Torres, S Radice, D Gilardi, C Correale, M Allocca, F Furfaro, M Alfieri, J Pascual, X Recalde, A Martínez, S Danese
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175126/p503-rapid-point-of-care-monitoring-of-anti-infliximab-antibodies-in-patients-with-inflammatory-bowel-disease-treated-with-the-reference-infliximab-or-ct-p13-in-routine-clinical-practice
#14
A Ametzazurra, N Rivera, A M Hernández, M P Arreba, E Ruiz, J Ortíz, M D C Muñoz, N Torres, J Pascual, A Martínez, M J Allande, D Nagore
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175115/p475-switching-from-infliximab-originator-to-ct-p13-is-not-related-to-increased-immunogenicity-in-ibd-patients-a-prospective-case-control-study
#15
G Fiorino, S Radice, D Gilardi, C Correale, M Allocca, F Furfaro, M Alfieri, D Nagore, L Del Rio, J Pascual, A Martínez, S Danese
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172988/p545-clinical-outcomes-following-a-switch-from-remicade%C3%A2-to-the-biosimilar-ct-p13-in-inflammatory-bowel-disease-patients-in-clinical-remission-preliminary-results
#16
L N Guerrero Puente, E Iglesias Flores, J M Benítez Cantero, M J Cárdenas Aranzana, R Medina Medina, I Salgueiro Rodríguez, P Aguilar Melero, B Manzanares Martin, V García-Sánchez
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172986/p663-switching-from-remicade%C3%A2-to-biosimilar-ct-p13-in-inflammatory-bowel-disease-patients-one-year-follow-up-of-a-prospective-observational-cohort-study
#17
L Smits, A Grelack, J Drenth, D de Jong, R Boshuizen, A van Esch, L Derikx, F Hoentjen
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172881/p582-the-pharmacoeconomic-impact-of-biosimilar-infliximab-ct-p13-in-europe-from-january-2015-to-june-2016
#18
S Han, S Kim, J Kim, D-H Kwon, J-S Choi, S-R Yoon, S-H Yun, D-S Kim, J-H Bae, H-J Choi, H-Y Sung, S-W Yoon
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172879/p487-effectiveness-and-safety-of-ct-p13-under-routine-care-in-paediatric-patients-with-inflammatory-bowel-disease
#19
Y H Choe, H R Yang, J S Moon, E Ryoo, S Kim, J H Lee, H J Kim, J H Park, M J Kim, S J Lee, S Y Lee
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172829/p500-effectiveness-and-safety-in-crohn-s-disease-patients-who-were-treated-with-ct-p13
#20
Y H Choe, S-H Lee, D I Park, J H Lee, H J Kim, Y-H Kim, C H Choi, C S Eun, S J Lee, S Lee
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
97571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"